Neuroleptic malignant syndrome

Public advisory - Donepezil 10 mg tablets: One lot recalled due to possible oversized tablets

Retrieved on: 
Saturday, November 25, 2023

Pro Doc Limitée is recalling one lot of Donepezil (donepezil hydrochloride) 10 mg tablets due to the possibility that some bottles might contain oversized tablets.

Key Points: 
  • Pro Doc Limitée is recalling one lot of Donepezil (donepezil hydrochloride) 10 mg tablets due to the possibility that some bottles might contain oversized tablets.
  • Health Canada is warning patients and their caregivers that taking an oversized tablet could receive up to three times the intended dose (i.e.
  • Donepezil is a prescription drug used for the symptomatic treatment of mild, moderate, and severe Alzheimer's disease.
  • If your pill bottle of Donepezil 10 mg tablets contains larger-than-normal tablets, or if you are unsure, return it to your pharmacy.

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

Retrieved on: 
Friday, August 18, 2023

"We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."

Key Points: 
  • "We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."
  • In clinical studies in Huntington's disease, treatment-emergent adverse events included somnolence and sedation, urticaria, rash and insomnia.
  • "Data also demonstrated INGREZZA was generally well tolerated and showed clinically meaningful improvement in adults with chorea associated with HD."
  • "The approval of INGREZZA for HD chorea means that people living with HD have a new treatment option to help manage their chorea symptoms, which is a welcomed milestone in efforts to improve care for families affected by HD."

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

Retrieved on: 
Wednesday, November 30, 2022

This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.

Key Points: 
  • This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.
  • We are thrilled and highly encouraged by the strides we have made with the USPTO and its continued acknowledgement of the novel and inventive nature of GIMOTI, said Matt DOnofrio, Chief Business Officer of Evoke Pharma.
  • Most common adverse reactions (5%) for GIMOTI are: dysgeusia, headache, and fatigue.These are not all of the possible side effects of GIMOTI.
  • Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects.

Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Thursday, October 20, 2022

SOLANA BEACH, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company will participate in the 2022 American College of Gastroenterology Annual Scientific Meeting taking place from October 21 – 26, 2022 in Charlotte, North Carolina. Also, as a nominee for the Healio Industry Breakthrough Product Award, Evoke will attend the Healio Disruptive Innovators Awards Program on Sunday, October 23rd, in Charlotte during the ACG meeting.

Key Points: 
  • FollowEvoke Pharmaon Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724
    FollowEvoke Pharmaon LinkedIn: https://www.linkedin.com/company/evoke-pharma/
    GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
  • Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
  • The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award

Retrieved on: 
Wednesday, September 14, 2022

SOLANA BEACH, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its flagship product, GIMOTI has been nominated for Healio’s Annual Disruptive Innovators Awards under the Healio Industry Breakthrough Award category. GIMOTI was selected amongst other novel gastroenterology products from major pharmaceutical companies.

Key Points: 
  • The Disruptive Innovators Awards hosted by Healio is an annual event to celebrate the trailblazers, movers, and industry name-makers that are creating a revolution in gastroenterology.
  • "We are extremely honored to receive the nomination for GIMOTI as a Healio Disruptive Innovator.
  • We look forward to the Healio organization's unveiling of the award winners in each category and encourage all Evoke supporters to access the Healio survey and vote for GIMOTI."
  • Most common adverse reactions (5%) for GIMOTI are: dysgeusia, headache, and fatigue.These are not all of the possible side effects of GIMOTI.

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Retrieved on: 
Wednesday, June 8, 2022

As previously disclosed, in early May, the Company utilized its at-the-market program to raise proceeds of approximately $7.1 million, net of commissions and fees.

Key Points: 
  • As previously disclosed, in early May, the Company utilized its at-the-market program to raise proceeds of approximately $7.1 million, net of commissions and fees.
  • Matt DOnofrio, MBA, Chief Business Officer of Evoke Pharma commented, We are pleased to regain compliance with the Nasdaq listing standards.
  • In conjunction, we are happy to announce that weve substantially bolstered our cash reserves and extended operational runway.
  • We believe the additional capital positions us to sustain and increase GIMOTI sales and to capitalize on future market opportunities.

Evoke Pharma to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022

In addition, management will be available for one-on-one meetings during the conference.

Key Points: 
  • In addition, management will be available for one-on-one meetings during the conference.
  • Registered investors will be able to request a meeting with management via the conference portal.
  • Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases.
  • Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects.

Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List

Retrieved on: 
Tuesday, April 19, 2022

This decision supports reimbursement for GIMOTI on the Texas Medicaid formulary and associated programs which provides healthcare to an estimated 5 million people.

Key Points: 
  • This decision supports reimbursement for GIMOTI on the Texas Medicaid formulary and associated programs which provides healthcare to an estimated 5 million people.
  • According to Texas Health and Human Services, preferred drugs are medications recommended by the Texas Drug Utilization Review Board for their efficaciousness, clinical significance, cost effectiveness, and safety.
  • The Medicaid Formulary contains all products, including those on the preferred drug list, available to people enrolled in Medicaid.
  • GIMOTI will be available for those that fail treatment with any preferred drug class.

Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape

Retrieved on: 
Thursday, March 10, 2022

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases.

Key Points: 
  • Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases.
  • The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
  • The gastric delay caused by gastroparesis can compromise absorption of orally administered medications.
  • FollowEvoke Pharmaon Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724
    FollowEvoke Pharmaon LinkedIn: https://www.linkedin.com/company/evoke-pharma/
    GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.